tirzepatide 3 month A real-world study of for weight loss in adults without diabetes mellitus Life After Tirzepatide | 3

Clinical Implications Because their mechanisms differ, side effects also vary

Dedicated cardiovascular outcome trials are ongoing to assess effects on major adverse cardiovascular events

Semaglutide, the active ingredient in Novo Nordisks blockbuster diabetes and weight-loss medications Ozempic and Wegovy, has been on the FDAs shortage list since March 2022

A total of 63.2% of the patients in the liraglutide arm lost at least 5% of their body weight compared with 27.1% in the placebo arm ( P 30% (79)

J Clin Endocrinol Metab (2017) 102(11):433341

We've spent years perfecting our macro calculator, and it'll take into account your height, weight, age, activity level and more